Ligand Partner CASI Pharmaceuticals Launches EVOMELA® in China
SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on
Tag: melphalan
CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection (Trademark: EVOMELA®)
National Medical Products Administration Approves Melphalan Hydrochloride For Injection (EVOMELA®, formulation based on SBECD aka. Captisol or Dexolve) as Treatment